248 related articles for article (PubMed ID: 25060518)
41. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
[No Abstract] [Full Text] [Related]
42. Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation.
Huang A; Ju HQ; Liu K; Zhan G; Liu D; Wen S; Garcia-Manero G; Huang P; Hu Y
Cancer Lett; 2016 Jul; 377(2):149-57. PubMed ID: 27132990
[TBL] [Abstract][Full Text] [Related]
43. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.
Williams AB; Nguyen B; Li L; Brown P; Levis M; Leahy D; Small D
Leukemia; 2013 Jan; 27(1):48-55. PubMed ID: 22858906
[TBL] [Abstract][Full Text] [Related]
44. A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia.
Smith CC; Levis MJ; Frankfurt O; Pagel JM; Roboz GJ; Stone RM; Wang ES; Severson PL; West BL; Le MH; Kayser S; Lam B; Hsu HH; Zhang C; Bollag G; Perl AE
Blood Adv; 2020 Apr; 4(8):1711-1721. PubMed ID: 32330242
[TBL] [Abstract][Full Text] [Related]
45. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
46. The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations.
Zhang W; Borthakur G; Gao C; Chen Y; Mu H; Ruvolo VR; Nomoto K; Zhao N; Konopleva M; Andreeff M
Cancer Res; 2016 Mar; 76(6):1528-37. PubMed ID: 26822154
[TBL] [Abstract][Full Text] [Related]
47. The Future of Targeting FLT3 Activation in AML.
Leick MB; Levis MJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
[TBL] [Abstract][Full Text] [Related]
48. A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia.
Sellmer A; Pilsl B; Beyer M; Pongratz H; Wirth L; Elz S; Dove S; Henninger SJ; Spiekermann K; Polzer H; Klaeger S; Kuster B; Böhmer FD; Fiebig HH; Krämer OH; Mahboobi S
Eur J Med Chem; 2020 May; 193():112232. PubMed ID: 32199135
[TBL] [Abstract][Full Text] [Related]
49. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.
Galanis A; Ma H; Rajkhowa T; Ramachandran A; Small D; Cortes J; Levis M
Blood; 2014 Jan; 123(1):94-100. PubMed ID: 24227820
[TBL] [Abstract][Full Text] [Related]
50. BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.
Fiskus W; Sharma S; Qi J; Shah B; Devaraj SG; Leveque C; Portier BP; Iyer S; Bradner JE; Bhalla KN
Mol Cancer Ther; 2014 Oct; 13(10):2315-27. PubMed ID: 25053825
[TBL] [Abstract][Full Text] [Related]
51. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.
Smith CC; Wang Q; Chin CS; Salerno S; Damon LE; Levis MJ; Perl AE; Travers KJ; Wang S; Hunt JP; Zarrinkar PP; Schadt EE; Kasarskis A; Kuriyan J; Shah NP
Nature; 2012 Apr; 485(7397):260-3. PubMed ID: 22504184
[TBL] [Abstract][Full Text] [Related]
52. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.
Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Döhner H; Döhner K; Schittenhelm MM
Mol Cancer; 2013 Mar; 12():19. PubMed ID: 23497317
[TBL] [Abstract][Full Text] [Related]
53. Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors.
Parmar A; Marz S; Rushton S; Holzwarth C; Lind K; Kayser S; Döhner K; Peschel C; Oostendorp RA; Götze KS
Cancer Res; 2011 Jul; 71(13):4696-706. PubMed ID: 21546568
[TBL] [Abstract][Full Text] [Related]
54. Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD
Li D; Li T; Shang Z; Zhao L; Xu Q; Tan J; Qin Y; Zhang Y; Cao Y; Wang N; Huang L; Zhu X; Zhou K; Chen L; Li C; Xie T; Yang Y; Wang J; Zhou J
Signal Transduct Target Ther; 2020 Mar; 5(1):21. PubMed ID: 32296014
[TBL] [Abstract][Full Text] [Related]
55. Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML.
Wang A; Wu H; Chen C; Hu C; Qi Z; Wang W; Yu K; Liu X; Zou F; Zhao Z; Wu J; Liu J; Liu F; Wang L; Stone RM; Galinksy IA; Griffin JD; Zhang S; Weisberg EL; Liu J; Liu Q
Oncotarget; 2016 May; 7(20):29131-42. PubMed ID: 27074558
[TBL] [Abstract][Full Text] [Related]
56. Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.
Jeon JY; Zhao Q; Buelow DR; Phelps M; Walker AR; Mims AS; Vasu S; Behbehani G; Blachly J; Blum W; Klisovic RB; Byrd JC; Garzon R; Baker SD; Bhatnagar B
Invest New Drugs; 2020 Apr; 38(2):340-349. PubMed ID: 31102119
[TBL] [Abstract][Full Text] [Related]
57. G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia.
Lee HK; Kim HW; Lee IY; Lee J; Lee J; Jung DS; Lee SY; Park SH; Hwang H; Choi JS; Kim JH; Kim SW; Kim JK; Cools J; Koh JS; Song HJ
Blood; 2014 Apr; 123(14):2209-19. PubMed ID: 24532805
[TBL] [Abstract][Full Text] [Related]
58. FLT3 inhibitors in acute myeloid leukemia.
Wu M; Li C; Zhu X
J Hematol Oncol; 2018 Dec; 11(1):133. PubMed ID: 30514344
[TBL] [Abstract][Full Text] [Related]
59. Targeting oncoprotein stability overcomes drug resistance caused by FLT3 kinase domain mutations.
Yu C; Kancha RK; Duyster J
PLoS One; 2014; 9(5):e97116. PubMed ID: 24849514
[TBL] [Abstract][Full Text] [Related]
60. Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance.
Staudt D; Murray HC; McLachlan T; Alvaro F; Enjeti AK; Verrills NM; Dun MD
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30332834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
